Investment Analysts’ Recent Ratings Changes for IQVIA (IQV)

Several analysts have recently updated their ratings and price targets for IQVIA (NYSE: IQV):

• 11/8/2024 – IQVIA was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/5/2024 – IQVIA had its price target lowered by analysts at JPMorgan Chase & Co. from $279.00 to $240.00. They now have an “overweight” rating on the stock.
• 11/4/2024 – IQVIA had its price target lowered by analysts at Morgan Stanley from $280.00 to $265.00. They now have an “overweight” rating on the stock.
• 11/4/2024 – IQVIA had its price target lowered by analysts at Truist Financial Co. from $286.00 to $265.00. They now have a “buy” rating on the stock.
• 11/1/2024 – IQVIA had its price target lowered by analysts at Barclays PLC from $260.00 to $255.00. They now have an “overweight” rating on the stock.
• 11/1/2024 – IQVIA had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $270.00 price target on the stock.
• 11/1/2024 – IQVIA had its price target lowered by analysts at Robert W. Baird from $256.00 to $223.00. They now have a “neutral” rating on the stock.
• 11/1/2024 – IQVIA had its price target lowered by analysts at BTIG Research from $290.00 to $260.00. They now have a “buy” rating on the stock.
• 11/1/2024 – IQVIA had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $270.00 to $265.00. They now have a “buy” rating on the stock.
• 11/1/2024 – IQVIA had its price target lowered by analysts at TD Cowen from $270.00 to $255.00. They now have a “buy” rating on the stock.
• 11/1/2024 – IQVIA had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $280.00 to $250.00. They now have a “buy” rating on the stock.
• 10/30/2024 – IQVIA was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 10/23/2024 – IQVIA had its price target lowered by analysts at JPMorgan Chase & Co. from $288.00 to $279.00. They now have an “overweight” rating on the stock.
• 10/22/2024 – IQVIA was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 10/15/2024 – IQVIA had its price target lowered by analysts at Barclays PLC from $275.00 to $260.00. They now have an “overweight” rating on the stock.
• 10/14/2024 – IQVIA was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 10/14/2024 – IQVIA had its price target lowered by analysts at Truist Financial Co. from $300.00 to $286.00. They now have a “buy” rating on the stock.
• 10/14/2024 – IQVIA is now covered by analysts at Redburn Atlantic. They set a “buy” rating and a $276.00 price target on the stock.
• 10/8/2024 – IQVIA had its price target lowered by analysts at Evercore ISI from $270.00 to $265.00. They now have an “outperform” rating on the stock.
• 9/27/2024 – IQVIA was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 9/20/2024 – IQVIA had its price target raised by analysts at Robert W. Baird from $251.00 to $256.00. They now have a “neutral” rating on the stock.

IQVIA Trading Down 1.0 %

Shares of NYSE:IQV traded down $2.08 during mid-day trading on Wednesday, hitting $211.49. The company had a trading volume of 3,190,976 shares, compared to its average volume of 1,118,086. IQVIA Holdings Inc. has a one year low of $197.37 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company has a market capitalization of $38.39 billion, a PE ratio of 27.75, a price-to-earnings-growth ratio of 2.20 and a beta of 1.51. The firm has a fifty day moving average price of $229.61 and a 200 day moving average price of $228.89.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 1.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On IQVIA

A number of large investors have recently made changes to their positions in the stock. Quantbot Technologies LP raised its stake in IQVIA by 389.3% in the third quarter. Quantbot Technologies LP now owns 15,705 shares of the medical research company’s stock valued at $3,722,000 after purchasing an additional 12,495 shares in the last quarter. D.A. Davidson & CO. raised its position in shares of IQVIA by 1.5% during the 3rd quarter. D.A. Davidson & CO. now owns 24,876 shares of the medical research company’s stock valued at $5,895,000 after buying an additional 375 shares in the last quarter. FMR LLC grew its position in IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in IQVIA by 0.9% in the third quarter. The Manufacturers Life Insurance Company now owns 454,984 shares of the medical research company’s stock valued at $107,818,000 after acquiring an additional 4,240 shares during the last quarter. Finally, Qsemble Capital Management LP raised its position in IQVIA by 169.2% during the third quarter. Qsemble Capital Management LP now owns 12,061 shares of the medical research company’s stock valued at $2,858,000 after purchasing an additional 7,580 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.